
Commentary|Videos|April 4, 2014
Trial Endpoints in Prostate Cancer
Author(s)Robert Dreicer, MD, MS, MACP, FASCO
Robert Dreicer, MD, MS, Cleveland Clinic Lerner College of Medicine, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.
Advertisement
Clinical Pearls
Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.
- Current trial endpoints needed for regulatory approval take longer to achieve in earlier disease states
- Until intermediate endpoints are applied in this disease, survival endpoints will remain difficult to reach in some disease stages
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5









































